Active ingredientTramazolineCat. No. P-T173-001CAS 1082-57-1Family · Pharmaceutical analytical standards
Tramazoline
A nasal decongestant of the alpha-sympathomimetic family, patented in 1961 and in medical use since 1962: it narrows the blood vessels of the nasal lining and reduces mucus secretion, clearing a blocked nose. This family brings together the active ingredient and pharmacopoeial impurities.
Did you know?Its molecule joins two parts: an imidazoline ring carrying an amino group and a tetrahydronaphthalene, a naphthalene in which one of the two rings carries four extra hydrogen atoms.
Go to the active ingredient →Active ingredientTramazolineCat. No. P-T173-001CAS 1082-57-1
Active ingredientTramazoline Hydrochloride MonohydrateCat. No. P-T173-002CAS 74195-73-6
Pharmacopoeial impurityTramazoline EP Impurity ACat. No. P-T173-003CAS 4751-46-6
Pharmacopoeial impurityTramazoline EP Impurity BCat. No. P-T173-004No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceTramazoline hydrochloride monohydrate CRSEDQM code Y0000072Family TramazolineImpurityTramazoline impurity A CRSEDQM code Y0000065Family TramazolineImpurityTramazoline impurity B CRSEDQM code Y0000066Family TramazolineNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.